Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients-Reference-Cited by-同舟云学术

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients

Published:2017-05-29 Issue: Volume:8 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Phillips Sandra,Mistry Sameer,Riva Antonio,Cooksley Helen,Hadzhiolova-Lebeau Tanya,Plavova Slava,Katzarov Krum,Simonova Marieta,Zeuzem Stephan,Woffendin Clive,Chen Pei-Jer,Peng Cheng-Yuan,Chang Ting-Tsung,Lueth Stefan,De Knegt Robert,Choi Moon-Seok,Wedemeyer Heiner,Dao Michael,Kim Chang-Wook,Chu Heng-Chen,Wind-Rotolo Megan,Williams Roger,Cooney Elizabeth,Chokshi Shilpa

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference79 articles.

1. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion;Levy;Cytokine Growth Factor Rev,2001

2. Regulation of effector and memory T-cell functions by type I interferon;Huber;Immunology,2011

3. Induction and function of type I and III interferon in response to viral infection;Levy;Curr Opin Virol,2011

4. Interferons and hepatitis C virus;Heim;Swiss Med Wkly,2012

5. IFN-alpha subtypes: distinct biological activities in anti-viral therapy;Gibbert;Br J Pharmacol,2013

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon lambda receptor-1 isoforms differentially influence gene expression and HBV replication in stem cell-derived hepatocytes;Antiviral Research;2024-01

2. Membrane-proximal motifs encode differences in signaling strength between type I and III interferon receptors;Science Signaling;2023-10-10

3. Type III interferon exerts thymic stromal lymphopoietin in mediating adaptive antiviral immune response;Frontiers in Immunology;2023-09-22

4. Synthetic Heterodimers of Type III Interferon Receptors Require TYK2 for STAT Activation;Journal of Interferon & Cytokine Research;2023-09-01

5. An HBV susceptibility variant of KNG1 modulates the therapeutic effects of interferons α and λ1 in HBV infection by promoting MAVS lysosomal degradation;eBioMedicine;2023-08